KR20200085364A - Trk 키나제 저해제로서의 매크로시클릭 화합물 - Google Patents

Trk 키나제 저해제로서의 매크로시클릭 화합물 Download PDF

Info

Publication number
KR20200085364A
KR20200085364A KR1020207019372A KR20207019372A KR20200085364A KR 20200085364 A KR20200085364 A KR 20200085364A KR 1020207019372 A KR1020207019372 A KR 1020207019372A KR 20207019372 A KR20207019372 A KR 20207019372A KR 20200085364 A KR20200085364 A KR 20200085364A
Authority
KR
South Korea
Prior art keywords
mmol
fluoro
pyrimidine
parazolo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207019372A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 웨이드 앤드류스
케빈 로날드 콘드로스키
줄리아 하스
위퉁 장
가브리엘 알. 콜라코브스키
정법 서
홍-원 양
퀴안 자오
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20200085364A publication Critical patent/KR20200085364A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020207019372A 2010-05-20 2011-05-13 Trk 키나제 저해제로서의 매크로시클릭 화합물 Ceased KR20200085364A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34676710P 2010-05-20 2010-05-20
US61/346,767 2010-05-20
US201061426716P 2010-12-23 2010-12-23
US61/426,716 2010-12-23
PCT/US2011/036452 WO2011146336A1 (en) 2010-05-20 2011-05-13 Macrocyclic compounds as trk kinase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024602A Division KR102132405B1 (ko) 2010-05-20 2011-05-13 Trk 키나제 저해제로서의 매크로시클릭 화합물

Publications (1)

Publication Number Publication Date
KR20200085364A true KR20200085364A (ko) 2020-07-14

Family

ID=44280661

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020207019372A Ceased KR20200085364A (ko) 2010-05-20 2011-05-13 Trk 키나제 저해제로서의 매크로시클릭 화합물
KR1020187011138A Expired - Fee Related KR102015402B1 (ko) 2010-05-20 2011-05-13 Trk 키나제 저해제로서의 매크로시클릭 화합물
KR1020197024602A Expired - Fee Related KR102132405B1 (ko) 2010-05-20 2011-05-13 Trk 키나제 저해제로서의 매크로시클릭 화합물
KR1020127033226A Expired - Fee Related KR101852169B1 (ko) 2010-05-20 2011-05-13 Trk 키나제 저해제로서의 매크로시클릭 화합물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187011138A Expired - Fee Related KR102015402B1 (ko) 2010-05-20 2011-05-13 Trk 키나제 저해제로서의 매크로시클릭 화합물
KR1020197024602A Expired - Fee Related KR102132405B1 (ko) 2010-05-20 2011-05-13 Trk 키나제 저해제로서의 매크로시클릭 화합물
KR1020127033226A Expired - Fee Related KR101852169B1 (ko) 2010-05-20 2011-05-13 Trk 키나제 저해제로서의 매크로시클릭 화합물

Country Status (34)

Country Link
US (8) US8933084B2 (enExample)
EP (4) EP2918588B1 (enExample)
JP (5) JP5832527B2 (enExample)
KR (4) KR20200085364A (enExample)
CN (3) CN105693720B (enExample)
AR (1) AR081919A1 (enExample)
AU (4) AU2011256380C1 (enExample)
BR (2) BR122019024201B1 (enExample)
CA (1) CA2800079C (enExample)
CL (1) CL2012003227A1 (enExample)
CO (1) CO6660502A2 (enExample)
CR (1) CR20170098A (enExample)
CY (2) CY1119345T1 (enExample)
DK (2) DK3205654T3 (enExample)
ES (3) ES2718043T3 (enExample)
HR (2) HRP20171140T1 (enExample)
HU (2) HUE035337T2 (enExample)
IL (2) IL223094B (enExample)
LT (2) LT2918588T (enExample)
ME (1) ME03376B (enExample)
MX (4) MX2012013467A (enExample)
MY (1) MY191934A (enExample)
NZ (1) NZ604708A (enExample)
PH (2) PH12012502276A1 (enExample)
PL (2) PL3205654T3 (enExample)
PT (2) PT2918588T (enExample)
RS (1) RS58537B1 (enExample)
RU (2) RU2594742C2 (enExample)
SG (3) SG10201506593XA (enExample)
SI (2) SI2918588T1 (enExample)
SM (2) SMT201700372T1 (enExample)
TW (4) TWI516493B (enExample)
UY (1) UY33395A (enExample)
WO (1) WO2011146336A1 (enExample)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
EP2822953B9 (en) * 2012-03-06 2017-06-21 Pfizer Inc Macrocyclic derivatives for the treatment of proliferative diseases
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
RU2664541C2 (ru) 2012-11-13 2018-08-20 Эррэй Биофарма Инк. Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
ES2664331T3 (es) 2012-11-13 2018-04-19 Array Biopharma, Inc. Compuestos de N-pirrolidinilo, N'-pirazolilurea, tiourea, guanidina y cianoguanidina como inhibidores de la cinasa Trka
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
EP3636649B1 (en) 2014-01-24 2024-02-14 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
PT3154959T (pt) 2014-05-15 2019-09-24 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka
TWI688567B (zh) * 2014-09-11 2020-03-21 美商特普醫葯公司 作為蛋白質激酶之調節劑的二芳基巨環
SG11201701116XA (en) * 2014-09-17 2017-03-30 Oncodesign Sa Macrocyclic rip2 kinase inhibitors
TR201904514T4 (tr) * 2014-09-17 2019-04-22 Oncodesign Sa Makrosiklik LRRK2 kinaz inhibitörleri.
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10377775B2 (en) 2014-12-04 2019-08-13 Shin-Etsu Chemical Co., Ltd. Method for producing polyalkylene glycol derivative having amino group at end
JP6460937B2 (ja) * 2014-12-04 2019-01-30 信越化学工業株式会社 末端にアミノ基を有するポリアルキレングリコール誘導体の製造方法
US9708350B2 (en) 2014-12-04 2017-07-18 Shin-Etsu Chemical Co., Ltd. Method for producing polyalkylene glycol derivative having amino group at end, polymerization initiator for use in the same, and alcohol compound as raw material for the polymerization initiator
HRP20240937T1 (hr) * 2014-12-15 2024-10-25 Cmg Pharmaceutical Co., Ltd. Heteroaril spoj sa kondeziranim prstenom i njihova primjena kao trk inhibitora
RU2017129757A (ru) 2015-01-23 2019-02-25 ДжиВиКей БИОСАЕНСЕЗ ПРАЙВИТ ЛИМИТЕД ИНГИБИТОРЫ TrkA КИНАЗЫ
EP3722441A1 (en) 2015-06-01 2020-10-14 Loxo Oncology Inc. Method of diagnosing a cancer for a treatment with a trk inhibitor
RU2732405C2 (ru) * 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
WO2017007759A1 (en) * 2015-07-06 2017-01-12 Tp Therapeutics, Inc. Diaryl macrocycle polymorph
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
US20180325901A1 (en) 2015-07-21 2018-11-15 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CA2998885C (en) 2015-09-24 2020-09-01 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
JP2018534296A (ja) * 2015-10-26 2018-11-22 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
HUE063877T2 (hu) 2016-05-18 2024-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása
JP2019527230A (ja) * 2016-07-28 2019-09-26 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 大環状キナーゼ阻害剤
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3066499A1 (en) * 2017-06-22 2018-12-27 Cyclenium Pharma Inc. Libraries of pyridine-containing macrocyclic compounds and methods of making and using the same
LT3658148T (lt) 2017-07-28 2024-09-10 Turning Point Therapeutics, Inc. Makrocikliniai junginiai ir jų panaudojimas
BR112020003783A2 (pt) 2017-08-23 2020-09-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. macrociclo contendo aminopirazol e pirimidina e composição farmacêutica e uso da mesma
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
MA50456A (fr) 2017-10-26 2020-09-02 Array Biopharma Inc Formulations d'un inhibiteur de kinase trk macrocyclique
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
KR102447084B1 (ko) * 2017-11-10 2022-09-23 앤젝스 파마수티컬, 인크. Trk 키나제 억제제로서의 거대 고리 화합물 및 그의 용도
KR102814342B1 (ko) * 2017-12-19 2025-05-29 터닝 포인트 테라퓨틱스, 인크. 질병 치료용 대환식 화합물
CN109956957B (zh) * 2017-12-22 2021-11-09 广州白云山医药集团股份有限公司白云山制药总厂 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
US11453672B2 (en) 2017-12-22 2022-09-27 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111848622A (zh) * 2018-01-23 2020-10-30 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
CN111511749B (zh) * 2018-01-30 2022-02-08 上海吉倍生物技术有限公司 具有大环分子结构的化合物及其用途
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN111788205B (zh) * 2018-02-28 2022-04-26 先声药业有限公司 吡唑并嘧啶衍生物及其用途
AU2019233204B2 (en) * 2018-03-14 2022-02-03 Fochon Biosciences, Ltd. Substituted (2-azabicyclo (3.1.0) hexan-2-yl) pyrazolo (1, 5-a) pyrimidine and imidazo (1, 2-b) pyridazine compounds as TRK kinases inhibitors
WO2019184955A1 (en) * 2018-03-28 2019-10-03 Fochon Pharmaceuticals, Ltd. Macrocyclic compounds as trk kinases inhibitors
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
EP3770161B1 (en) * 2018-04-16 2022-08-24 Shenzhen TargetRx, Inc. Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
PL3786167T3 (pl) * 2018-04-25 2024-11-25 Primegene (Beijing) Co., Ltd. Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanie
CN111918868B (zh) * 2018-05-04 2022-12-30 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
CN110577532B (zh) * 2018-06-08 2022-06-03 江苏威凯尔医药科技有限公司 原肌球蛋白受体激酶抑制剂及其制备方法和应用
WO2019233461A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 原肌球蛋白受体激酶抑制剂及其制备方法和应用
CN110627812B (zh) 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
KR102545594B1 (ko) 2018-07-31 2023-06-21 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
US20210403485A1 (en) * 2018-09-29 2021-12-30 Shandong Luye Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivative as selective trk inhibitor
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
WO2020094112A1 (zh) 2018-11-09 2020-05-14 山东轩竹医药科技有限公司 大环类酪氨酸激酶抑制剂及其用途
CN111171049B (zh) * 2018-11-09 2021-06-04 山东轩竹医药科技有限公司 酪氨酸激酶抑制剂及其用途
CN111253402B (zh) * 2018-11-30 2021-08-03 广州白云山医药集团股份有限公司白云山制药总厂 一种trk激酶抑制剂化合物的中间体化合物及制备方法
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
US20220177477A1 (en) 2019-03-19 2022-06-09 Central China Normal University Pyrazolopyrimidine compound, pharmaceutical composition, and application therefor
JP7595582B2 (ja) 2019-03-26 2024-12-06 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
BR112021022255A2 (pt) 2019-05-08 2022-01-18 Tyk Medicines Inc Composto usado como inibidor de quinase e aplicação do mesmo
CN113727984B (zh) * 2019-05-21 2024-03-15 浙江海正药业股份有限公司 大环类衍生物、及其制备方法和用途
CN112110938B (zh) * 2019-06-21 2021-11-09 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
WO2021037156A1 (zh) * 2019-08-28 2021-03-04 南京明德新药研发有限公司 一种致癌性融合激酶抑制剂的晶型及其应用
CN110804059B (zh) * 2019-09-30 2024-03-12 郑州泰基鸿诺医药股份有限公司 氨基甲酸酯类化合物、药物组合物及其应用
WO2021083345A1 (zh) * 2019-10-30 2021-05-06 先声药业有限公司 吡唑并嘧啶类化合物的制备方法及其中间体
UA129894C2 (uk) 2019-11-08 2025-09-03 Вентукс Біосціенціс, Інк. Ліганди псевдокінази tyk2
EP4063365A4 (en) * 2019-11-18 2023-01-11 Guangzhou Joyo Pharmatech Co., Ltd Compound as highly selective ros1 inhibitor and use thereof
AU2020402942B2 (en) 2019-12-13 2023-05-11 Scinnohub Pharmaceutical Co., Ltd Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof
CN113004305B (zh) * 2019-12-19 2024-04-09 赛诺哈勃药业（成都）有限公司 大环化合物及其制备方法和用途
CN113620974B (zh) * 2020-05-08 2023-01-31 山东轩竹医药科技有限公司 大环类酪氨酸激酶抑制剂的晶型及其制备方法
CN111777549A (zh) * 2020-07-07 2020-10-16 中瀚(齐河县)生物医药科技有限公司 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺
JP7713619B2 (ja) * 2020-07-10 2025-07-28 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大員環分子およびそれらの使用
CN114073704B (zh) * 2020-08-14 2023-08-11 赛诺哈勃药业（成都）有限公司 具有大环结构的含氟并杂环衍生物的应用
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法
CN111875620B (zh) * 2020-09-28 2020-12-11 上海美迪西生物医药股份有限公司 吡唑并嘧啶类大环衍生物及其应用
WO2022150584A1 (en) * 2021-01-08 2022-07-14 Yale University Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use
TWI804266B (zh) * 2021-04-07 2023-06-01 大陸商上海齊魯製藥研究中心有限公司 Tyk2抑制劑及其用途
WO2022242688A1 (zh) * 2021-05-18 2022-11-24 广州嘉越医药科技有限公司 一种含氰基取代的大环类化合物的晶型及其制备方法
CN115884776B (zh) * 2021-06-15 2024-07-23 中国医药研究开发中心有限公司 杂环大环化合物及其医药用途
CN117597128A (zh) * 2021-08-23 2024-02-23 正大天晴药业集团股份有限公司 含有氨基的大环化合物在治疗trk激酶介导的肿瘤中的用途
CN113754657B (zh) * 2021-09-22 2023-01-17 广州白云山医药集团股份有限公司白云山制药总厂 大环类化合物的晶型及其制备方法和应用
CN113582994B (zh) * 2021-09-28 2022-02-11 北京鑫开元医药科技有限公司 具有trk激酶抑制活性的化合物、制备方法、组合物及其用途
MX2024008413A (es) * 2022-01-05 2024-09-17 Blossomhill Therapeutics Inc Compuestos macrocíclicos y uso como inhibidores de cinasas.
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
WO2025137541A1 (en) * 2023-12-22 2025-06-26 Neuron23, Inc. Kinase modulators and methods of use thereof

Family Cites Families (324)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US755047A (en) * 1902-03-17 1904-03-22 Alexander Roth Robertson Bottle-seal.
EP0009517A1 (en) 1978-10-04 1980-04-16 THE PROCTER & GAMBLE COMPANY Vaginal contraceptive
ATE233245T1 (de) 1993-11-30 2003-03-15 Searle & Co Substituierte pyrazolyl-benzolsulfonamide und ihre verwendung als cyclooxygenaseii inhibitoren
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
DE69736428T2 (de) 1996-05-08 2007-08-30 Biogen Idec Ma Inc., Cambridge RET-LIGAND 3 (RetL3), UM NEURALES UND RENALES WACHSTUM ZU STIMULIEREN
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
US6682921B1 (en) 1996-08-21 2004-01-27 New York University Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
JP3898296B2 (ja) 1996-08-28 2007-03-28 ポーラ化成工業株式会社 ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬
EP0979231B1 (en) 1997-04-25 2004-11-24 Takeda Chemical Industries, Ltd. Condensed pyridazine derivatives, their production and use
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
WO2001016169A2 (en) 1999-09-01 2001-03-08 Biogen, Inc. RET LIGAND 5 (Retl5) FROM HUMAN AND MOUSE
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
FI20000403A0 (fi) 2000-02-22 2000-02-22 Hannu Sariola GDNF perhesukuisten yhdisteiden käyttö kivessyövän hoitoon tarkoitettujen tuotteiden valmistamiseksi
MXPA02012602A (es) 2000-06-22 2003-05-14 Genentech Inc Anticuerpos monoclonales agonistas anti-trk-c.
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
CN1684708A (zh) 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
KR20040097375A (ko) 2002-04-23 2004-11-17 시오노기 앤드 컴파니, 리미티드 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
JP2005535675A (ja) 2002-07-24 2005-11-24 ユニバーシティ・オブ・シンシナティ 変異型ｒｅｔキナーゼ関連疾患を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド
JP4024624B2 (ja) 2002-08-26 2007-12-19 富士通株式会社 半導体装置の製造方法及び製造装置
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
RU2357967C2 (ru) * 2002-09-16 2009-06-10 Глаксо Груп Лимитед ПРОИЗВОДНЫЕ ПИРАЗОЛО[3, 4-b]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ), ПРИМЕНЕНИЕ (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ)
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7262199B2 (en) 2002-12-11 2007-08-28 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2004082458A2 (en) 2003-02-21 2004-09-30 The Johns Hopkins University Tyrosine kinome
JP2004277337A (ja) * 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
JP2006522744A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
EP1619203A1 (en) 2003-04-28 2006-01-25 Galpharma Co., Ltd. Galectin 9-inducing factor
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
AU2004274051A1 (en) * 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
BRPI0416935A (pt) 2003-11-28 2007-01-16 Novartis Ag derivados de diaril ureia no tratamento de doenças dependentes de quìnase de proteìna
CA2549869C (en) * 2003-12-18 2015-05-05 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
DK1696920T3 (en) 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
UA91677C2 (ru) 2004-03-30 2010-08-25 Интермюн, Инк. Макроциклические соединения как ингибиторы вирусной репликации
EP2329902A1 (en) 2004-06-25 2011-06-08 Mitsubishi Materials Corporation Metal colloid particles, metal colloid and use of the colloid
CA2575808A1 (en) 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060127982A1 (en) 2004-10-29 2006-06-15 Shih Jason C Development of an asporogenic bacillus licheniformis and production of keratinase therefrom
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US7452847B2 (en) 2004-11-02 2008-11-18 Ricoh Company, Ltd. Reversible thermosensitive recording medium, reversible thermosensitive recording label, reversible thermosensitive recording device, image processing apparatus, and image processing method
US7528138B2 (en) 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
AU2006215394B2 (en) 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
CN101119996A (zh) 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
EP1848506A2 (en) 2005-02-18 2007-10-31 Attenuon, LLC Pyrimidine-fused diazepine derivatives and indole-fused pteridines
EP1869049B1 (en) * 2005-03-21 2009-03-04 Eli Lilly And Company Imidazopyridazine compounds
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
EP1874731A4 (en) 2005-04-15 2009-08-05 Cylene Pharmaceuticals Inc CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION
WO2006115452A1 (en) 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
AU2006248780B2 (en) 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US20100047777A1 (en) 2005-05-26 2010-02-25 The Johns Hopkins University Methods for identifying mutations in coding and non-coding dna
CN101233129A (zh) 2005-05-31 2008-07-30 普法尔家族联合企业（1996.7.9） 取代的联芳杂环衍生物作为蛋白激酶抑制剂治疗癌症及其他疾病
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
CN100406650C (zh) 2005-06-05 2008-07-30 徐斌 一种抗特大变位的模块式梳型桥梁伸缩缝装置
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
US20070025540A1 (en) 2005-07-07 2007-02-01 Roger Travis Call center routing based on talkativeness
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
GEP20105124B (en) * 2005-07-25 2010-11-25 Array Biopharma Inc Novel macrocyclic inhibitors of hepatitis c virus replication
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
CN101232871A (zh) 2005-08-03 2008-07-30 伊士曼化工公司 生育酚聚乙二醇琥珀酸酯粉末及其制备方法
AU2006283592A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
AU2006284096B2 (en) 2005-08-25 2012-03-29 Avro Life Sciences, Inc. Polymer conjugates of K-252a and derivatives thereof
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
WO2007044407A2 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
UA93990C2 (ru) * 2005-10-11 2011-03-25 Интермюн, Инк. Соединения и способ ингибирования репликации вируса гепатита c
WO2007057782A2 (en) 2005-10-11 2007-05-24 Centre National De La Recherche Scientifique (Cnrs) 3 -hydroxyflavone derivatives for the detection and the quantification of cell apoptosis
EP1948663B1 (en) 2005-10-21 2011-09-14 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
US7803806B2 (en) 2005-11-03 2010-09-28 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
US20070149523A1 (en) 2005-11-14 2007-06-28 Jan Ehlert Thiazole Analogues and Uses Thereof
EP1785420A1 (en) 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
WO2007057397A1 (en) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
US7795273B2 (en) 2005-12-08 2010-09-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
AU2007209689B2 (en) 2006-01-27 2012-03-15 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
WO2007102679A1 (en) 2006-03-06 2007-09-13 Je Il Pharmaceutical Co., Ltd. Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
RU2008139599A (ru) 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
RU2008140382A (ru) 2006-03-16 2010-04-27 Новартис АГ (CH) Гетероциклические органические соединения, например, для лечения меланомы
TWI409267B (zh) 2006-03-17 2013-09-21 Ambit Biosciences Corp 治療疾病用之咪唑并噻唑化合物
GB0606805D0 (en) 2006-04-04 2006-05-17 Novartis Ag Organic compounds
UA95799C2 (en) 2006-04-26 2011-09-12 Ф. Хоффманн-Ля Рош Аг Pharmaceutical compounds
EP2018167A4 (en) 2006-05-15 2010-07-14 Irm Llc COMPOSITIONS AND METHODS AS INHIBITORS OF FGF RECEPTOR KINASES
US7389632B2 (en) 2006-06-10 2008-06-24 Uhlmann Pac-Systeme Gmbh & Co. Kg Apparatus for distributing small objects in a fill station
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TWI419889B (zh) 2006-07-05 2013-12-21 Mitsubishi Tanabe Pharma Corp 吡唑并〔１，５-ａ〕嘧啶化合物
JPWO2008016131A1 (ja) 2006-08-04 2009-12-24 武田薬品工業株式会社 縮合複素環化合物
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
US20110021513A1 (en) 2006-09-07 2011-01-27 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
US20110195072A1 (en) 2006-09-12 2011-08-11 Anne Boulay Non-neuroendocrine cancer therapy
AU2007294686B2 (en) 2006-09-15 2013-10-31 Equinox Sciences, Llc Kinase inhibitor compounds
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
EP1918291A1 (en) 2006-10-30 2008-05-07 Novartis AG 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators
CA2667487C (en) 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP3048099A3 (en) 2006-11-15 2016-09-21 YM BioSciences Australia Pty Ltd Inhibitors of kinase activity
US20080199426A1 (en) 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
JP2010516692A (ja) 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
ES2541660T3 (es) * 2007-02-08 2015-07-23 Janssen Sciences Ireland Uc Inhibidores del VHC macrocíclicos sustituidos con pirimidina
US20080234267A1 (en) 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
EP2137187A1 (en) 2007-03-28 2009-12-30 Inovacia AB Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
UA101611C2 (ru) 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
US20110189167A1 (en) 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
EP2152688A1 (en) 2007-05-04 2010-02-17 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
EP2170827B1 (en) * 2007-06-21 2013-08-14 Janssen Pharmaceutica, N.V. Indolin-2-ones and aza-indolin-2-ones
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
US20100209488A1 (en) 2007-07-16 2010-08-19 The Regents Of The University Of California Protein kinase modulating compounds and methods for making and using them
PL2176231T3 (pl) 2007-07-20 2017-04-28 Nerviano Medical Sciences S.R.L. Podstawione pochodne indazolu aktywne jako inhibitory kinazy
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
RS53661B1 (sr) 2007-08-10 2015-04-30 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
EP2025678A1 (en) 2007-08-17 2009-02-18 Oncalis AG Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CN101883774A (zh) 2007-10-16 2010-11-10 惠氏有限责任公司 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途
JP2011501760A (ja) 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのｔｒｋｂ抗体の使用
WO2009060197A1 (en) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
EP2225247A1 (en) 2007-11-28 2010-09-08 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
CN102015769B (zh) 2008-01-17 2014-12-10 Irm责任有限公司 改进的抗-trkb抗体
TW200938542A (en) 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
US20090209496A1 (en) 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
JP5628145B2 (ja) 2008-03-19 2014-11-19 ケムブリッジ・コーポレーション 新規チロシンキナーゼ阻害剤
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
JP5492194B2 (ja) 2008-05-13 2014-05-14 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
EP2313091A4 (en) 2008-07-14 2012-04-04 Univ Kingston PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
US8946226B2 (en) 2008-07-29 2015-02-03 Nerviano Medical Sciences S.R.L. Use of CDK inhibitor for the treatment of glioma
US20100075916A1 (en) 2008-09-05 2010-03-25 Auspex Pharmaceuticals, Inc. Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
EP2161271A1 (en) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
WO2010036629A2 (en) 2008-09-26 2010-04-01 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
CA2740792C (en) 2008-10-31 2016-06-21 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
JP5686736B2 (ja) 2008-11-06 2015-03-18 アムビト ビオスシエンセス コルポラチオン プロテインキナーゼモジュレーターとしてのイミダゾロチアゾール化合物
US8912194B2 (en) 2008-11-24 2014-12-16 Nerviano Medical Sciences S.R.L. CDK inhibitor for the treatment of mesothelioma
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
AU2010213578B2 (en) 2009-02-12 2015-01-29 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
TWI410418B (zh) 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
EP3009428B1 (en) 2009-05-08 2018-02-21 Astellas Pharma Inc. Diamino heterocyclic carboxamide compound
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
KR101147550B1 (ko) 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
KR101116756B1 (ko) 2009-10-27 2012-03-13 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
US8404677B2 (en) 2009-10-29 2013-03-26 Genosco Kinase inhibitors
WO2011060295A1 (en) 2009-11-13 2011-05-19 Genosco Kinase inhibitors
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
EP2528925B1 (en) 2010-01-29 2017-07-05 Hanmi Science Co., Ltd. THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
ES2594927T3 (es) 2010-02-18 2016-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para prevenir las metástasis cancerosas
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8543395B2 (en) 2010-05-18 2013-09-24 Shazam Entertainment Ltd. Methods and systems for performing synchronization of audio with corresponding textual transcriptions and determining confidence values of the synchronization
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
CA2808577C (en) 2010-08-19 2018-09-25 Abbott Laboratories Anti-ngf antibodies and their use
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012047017A2 (ko) 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US8618146B2 (en) 2011-01-03 2013-12-31 Dr. Reddy's Laboratories Limited Epothilone compound formulations
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
WO2012135631A1 (en) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
PT2693881T (pt) 2011-04-01 2019-12-09 Univ Utah Res Found Análogos de n-fenilpirimidin-2-amina substituídos como inibidores da axl cinase
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
WO2013016720A2 (en) 2011-07-28 2013-01-31 Gerinda Therapeutics, Inc. Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
EP2740742B1 (en) 2011-08-04 2018-03-14 National Cancer Center Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
WO2013036232A2 (en) 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
US20150306086A1 (en) 2011-11-14 2015-10-29 Tesaro, Inc. Modulating certain tyrosine kinases
WO2013088257A1 (en) 2011-12-12 2013-06-20 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
BR112014015720B1 (pt) 2011-12-30 2020-03-17 Hanmi Pharm. Co., Ltd. Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
ES2605388T3 (es) 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Compuesto inhibidor de Trk
AU2013259267A1 (en) 2012-05-10 2014-11-06 Synta Pharmaceuticals Corp. Treating cancer with Hsp90 inhibitory compounds
ES2751944T3 (es) 2012-05-23 2020-04-02 Nerviano Medical Sciences Srl Proceso para la preparación de N-[5-(3,5-difluoro-bencil)-1H-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
JPWO2014017491A1 (ja) 2012-07-26 2016-07-11 国立研究開発法人国立がん研究センター Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子
EP2689778A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
CA2882759C (en) 2012-08-31 2018-11-20 The Regents Of The University Of Colorado Detection of the ntrk1-mprip gene fusion for cancer diagnosis
US20140121239A1 (en) 2012-09-07 2014-05-01 Exelixis, Inc. Method of treating lung adenocarcinoma
US20140084039A1 (en) 2012-09-24 2014-03-27 Electro Scientific Industries, Inc. Method and apparatus for separating workpieces
SG11201502211QA (en) 2012-09-25 2015-05-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
JP2014082984A (ja) 2012-10-23 2014-05-12 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
ES2755772T3 (es) 2012-11-07 2020-04-23 Nerviano Medical Sciences Srl Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas
AR093457A1 (es) 2012-11-12 2015-06-10 Cephalon Inc Derivados de bendamustina y metodos para utilizarlos
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
RU2664541C2 (ru) 2012-11-13 2018-08-20 Эррэй Биофарма Инк. Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
ES2664331T3 (es) 2012-11-13 2018-04-19 Array Biopharma, Inc. Compuestos de N-pirrolidinilo, N'-pirazolilurea, tiourea, guanidina y cianoguanidina como inhibidores de la cinasa Trka
JP2016502536A (ja) 2012-11-29 2016-01-28 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 腫瘍転移を防止し、がんを処置および予後診断し、推定転移阻害剤である薬剤を同定する方法
CN103848785B (zh) 2012-12-04 2016-07-13 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
FR3000493A1 (fr) 2012-12-28 2014-07-04 Oribase Pharma Nouveaux inhibiteurs de proteines kinases
FR3000494B1 (fr) 2012-12-28 2015-08-21 Oribase Pharma Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
RU2671847C2 (ru) 2012-12-28 2018-11-07 Кристалдженомикс, Инк. Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона
FR3000492B1 (fr) 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
HUE042591T2 (hu) 2013-02-19 2019-07-29 Ono Pharmaceutical Co TRK-gátló vegyület
US20160010068A1 (en) 2013-02-22 2016-01-14 Boris C. Bastian Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets
WO2014134096A1 (en) 2013-02-27 2014-09-04 Oregon Health & Science University Methods of treating cancers characterized by aberrent ros1 activity
EP4253558B1 (en) 2013-03-15 2025-07-02 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
PE20151538A1 (es) 2013-03-15 2015-11-18 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
WO2014152777A2 (en) 2013-03-15 2014-09-25 Insight Genetics, Inc. Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors
EP2968551B1 (en) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
EP2986736B1 (en) 2013-04-17 2019-09-18 Life Technologies Corporation Gene fusions and gene variants associated with cancer
WO2015003658A1 (en) 2013-07-11 2015-01-15 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators and methods of use
WO2015012397A1 (ja) 2013-07-26 2015-01-29 公益財団法人がん研究会 Ｎｔｒｋ３融合体の検出法
EP3027655B1 (en) 2013-07-30 2019-08-21 Blueprint Medicines Corporation Ntrk2 fusions
US20150057335A1 (en) 2013-08-20 2015-02-26 National Cancer Center Novel fusion genes identified in lung cancer
RU2016111675A (ru) 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
CA2927148A1 (en) 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer
WO2015064621A1 (ja) 2013-10-29 2015-05-07 公益財団法人がん研究会 新規融合体及びその検出法
ES2734213T3 (es) 2013-11-27 2019-12-04 Enplas Corp Emisor y tubo para riego por goteo
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
EP3076966A2 (en) 2013-12-02 2016-10-12 BerGenBio AS Use of kinase inhibitors
EP3636649B1 (en) 2014-01-24 2024-02-14 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
ES2874533T3 (es) 2014-02-05 2021-11-05 VM Oncology LLC Composiciones de compuestos y usos de los mismos
EP3738952A1 (en) 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
PT3154959T (pt) 2014-05-15 2019-09-24 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka
WO2015183837A1 (en) 2014-05-27 2015-12-03 Brian Haynes Compositions, methods, and uses related to ntrk2-tert fusions
WO2015184443A1 (en) 2014-05-30 2015-12-03 The Regents Of The University Of Colorado Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
CN105222097A (zh) 2014-06-26 2016-01-06 欧普照明股份有限公司 一种灯具及其光学模组
AU2015291522B2 (en) 2014-07-17 2018-12-06 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
AU2015296010A1 (en) 2014-08-01 2017-02-02 Pharmacyclics Llc Biomarkers for predicting response of DLBCL to treatment with a BTK inhibitor
KR20170042591A (ko) 2014-08-18 2017-04-19 오노 야꾸힝 고교 가부시키가이샤 Trk 저해 화합물의 산부가염
WO2016038519A1 (en) 2014-09-08 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
PL3191450T3 (pl) 2014-09-10 2019-08-30 Glaxosmithkline Intellectual Property Development Limited Pochodne pirydonu jako inhibitory kinazy rearanżowanej podczas transfekcji (ret)
US9879021B2 (en) 2014-09-10 2018-01-30 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
TWI538914B (zh) 2014-10-03 2016-06-21 國立交通大學 蛋白質激酶之選擇性抑制劑、其醫藥組成物及其用途
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
HRP20240937T1 (hr) 2014-12-15 2024-10-25 Cmg Pharmaceutical Co., Ltd. Heteroaril spoj sa kondeziranim prstenom i njihova primjena kao trk inhibitora
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
KR101675984B1 (ko) 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
WO2016141169A1 (en) 2015-03-03 2016-09-09 Caris Mpi, Inc. Molecular profiling for cancer
CA2980078C (en) 2015-03-16 2024-03-12 Personal Genome Diagnostics Inc. Systems and methods for analyzing nucleic acid
US10364247B2 (en) 2015-04-21 2019-07-30 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Preparation and use of novel protein kinase inhibitors
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
EP3303382A4 (en) 2015-05-29 2018-12-19 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
EP3722441A1 (en) 2015-06-01 2020-10-14 Loxo Oncology Inc. Method of diagnosing a cancer for a treatment with a trk inhibitor
US9782400B2 (en) 2015-06-19 2017-10-10 Macau University Of Science And Technology Oncogenic ROS1 and ALK kinase inhibitor
AU2015101722A4 (en) 2015-06-19 2016-05-19 Macau University Of Science And Technology Oncogenic ros1 and alk kinase inhibitor
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
GB201512365D0 (en) 2015-07-15 2015-08-19 King S College London Novel therapy
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
KR101766194B1 (ko) 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
WO2017049462A1 (zh) 2015-09-22 2017-03-30 合肥中科普瑞昇生物医药科技有限公司 一类新型的flt3激酶抑制剂及其用途
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法
EA038890B1 (ru) 2015-11-02 2021-11-03 Блюпринт Медсинс Корпорейшн Ингибиторы ret
US20190002988A1 (en) 2015-12-08 2019-01-03 Boehringer Ingelheim International Gmbh Method of using a ret fusion gene as a biomarker to select non small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment
JP6871869B2 (ja) 2016-01-15 2021-05-19 公益財団法人がん研究会 新規融合体及びその検出法
WO2017127835A2 (en) 2016-01-22 2017-07-27 The Medicines Company Aqueous formulations and methods of preparation and use thereof
TWI620748B (zh) 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
EP3269370B1 (en) 2016-02-23 2020-01-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
TW201733580A (zh) 2016-03-11 2017-10-01 小野藥品工業股份有限公司 Ｔｒｋ抑制劑抵抗性的癌治療劑
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
EP3442535B1 (en) 2016-04-15 2022-06-01 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
SG11201808878UA (en) 2016-04-15 2018-11-29 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
CA3021445A1 (en) 2016-04-19 2017-10-26 Exelixis, Inc. Triple negative breast cancer treatment method
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
HUE063877T2 (hu) 2016-05-18 2024-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása
WO2017201156A1 (en) 2016-05-18 2017-11-23 Duke University Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
US20170349953A1 (en) 2016-06-01 2017-12-07 Roche Sequencing Solutions, Inc. Novel mutations in anaplastic lymphoma kinase predicting response to alk inhibitor therapy in lung cancer patients
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CA3049452A1 (en) 2017-01-20 2018-07-26 Gisela Schwab Combinations of cabozantinib and atezolizumab to treat cancer
CN108456163A (zh) 2017-02-20 2018-08-28 中国科学院上海药物研究所 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
MA50456A (fr) 2017-10-26 2020-09-02 Array Biopharma Inc Formulations d'un inhibiteur de kinase trk macrocyclique

Also Published As

Publication number Publication date
UY33395A (es) 2012-11-30
CN110003209B (zh) 2022-01-25
AU2016203348A1 (en) 2016-06-16
RU2012155278A (ru) 2014-06-27
PH12015500190A1 (en) 2015-10-19
CN102971322A (zh) 2013-03-13
MX382699B (es) 2025-03-13
TW201202254A (en) 2012-01-16
MX2019006154A (es) 2019-08-21
MX365251B (es) 2019-05-28
AU2011256380A1 (en) 2013-01-10
US10647730B2 (en) 2020-05-12
KR20130086951A (ko) 2013-08-05
KR101852169B1 (ko) 2018-04-26
TWI667241B (zh) 2019-08-01
CN105693720B (zh) 2019-01-18
US20170107232A1 (en) 2017-04-20
KR102015402B1 (ko) 2019-08-28
JP5832527B2 (ja) 2015-12-16
SI3205654T1 (sl) 2019-07-31
TW201625640A (zh) 2016-07-16
AU2011256380C1 (en) 2016-09-08
IL257104A (en) 2018-03-29
EP2918588B1 (en) 2017-05-03
CR20170098A (es) 2017-07-17
IL257104B (en) 2021-03-25
EP2571883B1 (en) 2015-01-07
MX383400B (es) 2025-03-13
AU2016203348B2 (en) 2018-08-09
CN105693720A (zh) 2016-06-22
PH12015500190B1 (en) 2015-10-19
CL2012003227A1 (es) 2013-02-08
JP2013530142A (ja) 2013-07-25
SMT201700372T1 (it) 2017-09-07
WO2011146336A1 (en) 2011-11-24
ME03376B (me) 2020-01-20
US9750744B2 (en) 2017-09-05
RU2594742C2 (ru) 2016-08-20
AR081919A1 (es) 2012-10-31
BR112012029405A2 (pt) 2016-12-06
LT3205654T (lt) 2019-05-27
IL223094A0 (en) 2013-02-03
HK1215245A1 (en) 2016-08-19
ES2534335T3 (es) 2015-04-21
US9902741B2 (en) 2018-02-27
CY1119345T1 (el) 2018-02-14
TW201936197A (zh) 2019-09-16
IL223094B (en) 2018-05-31
CY1121688T1 (el) 2020-07-31
JP2021054840A (ja) 2021-04-08
HRP20171140T1 (hr) 2017-10-06
PT3205654T (pt) 2019-04-22
AU2018208676A1 (en) 2018-08-09
TWI734134B (zh) 2021-07-21
SMT201900203T1 (it) 2019-05-10
RU2735545C2 (ru) 2020-11-03
ES2628418T3 (es) 2017-08-02
MX2012013467A (es) 2013-04-29
HUE035337T2 (en) 2018-05-02
RU2016128920A (ru) 2018-12-07
JP6283636B2 (ja) 2018-02-21
US8933084B2 (en) 2015-01-13
EP3521291A1 (en) 2019-08-07
US20170283435A1 (en) 2017-10-05
NZ604708A (en) 2015-05-29
KR20180043407A (ko) 2018-04-27
CA2800079C (en) 2020-09-15
EP3205654B1 (en) 2019-01-02
RU2016128920A3 (enExample) 2019-12-25
JP2015221834A (ja) 2015-12-10
BR122019024201B1 (pt) 2021-08-03
PL2918588T3 (pl) 2017-10-31
SG10201506591TA (en) 2015-09-29
EP2571883A1 (en) 2013-03-27
SG185644A1 (en) 2012-12-28
TWI609019B (zh) 2017-12-21
US20150336970A1 (en) 2015-11-26
BR112012029405B1 (pt) 2021-01-05
CN110003209A (zh) 2019-07-12
LT2918588T (lt) 2017-08-25
DK2918588T3 (en) 2017-08-28
PH12012502276A1 (en) 2015-04-22
SI2918588T1 (sl) 2017-09-29
AU2011256380B2 (en) 2016-02-25
EP2918588A1 (en) 2015-09-16
JP2019104756A (ja) 2019-06-27
AU2016203348C1 (en) 2020-11-12
MY191934A (en) 2022-07-19
HRP20190559T1 (hr) 2019-06-14
PL3205654T3 (pl) 2019-08-30
EP3205654A1 (en) 2017-08-16
PT2918588T (pt) 2017-06-29
US20200291026A1 (en) 2020-09-17
CN102971322B (zh) 2016-02-17
US9493476B2 (en) 2016-11-15
US20130203776A1 (en) 2013-08-08
AU2020205339A1 (en) 2020-08-06
TWI516493B (zh) 2016-01-11
JP2017082018A (ja) 2017-05-18
CO6660502A2 (es) 2013-04-30
ES2718043T3 (es) 2019-06-27
DK3205654T3 (en) 2019-04-15
HK1181756A1 (en) 2013-11-15
AU2018208676B2 (en) 2020-07-30
US20170112842A1 (en) 2017-04-27
US9840519B2 (en) 2017-12-12
KR102132405B1 (ko) 2020-07-09
RS58537B1 (sr) 2019-04-30
US20190031684A1 (en) 2019-01-31
US9718822B2 (en) 2017-08-01
KR20190101498A (ko) 2019-08-30
BR112012029405A8 (pt) 2019-12-17
CA2800079A1 (en) 2011-11-24
TW201819388A (zh) 2018-06-01
HUE044025T2 (hu) 2019-09-30
US20170114059A1 (en) 2017-04-27
JP6523356B2 (ja) 2019-05-29
SG10201506593XA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
KR102132405B1 (ko) Trk 키나제 저해제로서의 매크로시클릭 화합물
HK1243058A1 (en) Macrocyclic compounds as trk kinase inhibitors
HK1181756B (en) Macrocyclic compounds as trk kinase inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200703

Application number text: 1020197024602

Filing date: 20190822

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200803

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200806

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210118

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200806

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I